Search
Close this search box.

Catalyst Clinical Research Announces Executive Changes | Catalyst Clinical Research

Nik Morton assumes CEO role, Nick Dyer pivots to new, expanded leadership position

Catalyst Clinical Research announced that Nik Morton assumed its CEO role on 12 February 2024. Prior to this move Nik served as the company’s President and COO. Having joined Catalyst as its COO in 2022. Nik moves into his new position while Nick Dyer, Catalyst’s former CEO, shifts his focus to lead the strategic growth of several companies while overseeing the continued development and evolution of Catalyst and Genpro, businesses within Project Constellation Holdings. 

“Nik is an experienced clinical research executive and is uniquely qualified to assume the CEO role,” said Nick Dyer, Executive Board Chair for Project Constellation Holdings, the parent company of Catalyst Clinical Research and Genpro Research. “While working with Nik, I have seen a leader who values Catalyst building upon its industry-leading approaches while maintaining our vibrant company culture. I look forward to continuing to work with him.” 

Catalyst Clinical Research will continue to provide CRO services, and the product team of Genpro Research will continue providing AI-enabled research, as well as publishing and writing tools for life science companies.  

Nick will continue to provide support and advice to leaders at Catalyst Clinical Research and Genpro Research. In his role as the Executive Board Chair for Project Constellation Holdings, Nick will partner with QHP Capital, Catalyst, and Genpro leadership to review monthly performance, discuss expansion strategies, and investigate and develop growth strategies and, for those approved, implementation plans for adjacent business lines.  

In addition, Nick plans to assist with recruiting efforts for senior leaders and work to optimize Project Constellation Holdings relationships with existing and potential investors.  

Nik has worked closely with Nick and the broader Catalyst executive leadership team for nearly two years, and he is ideally placed to take up his new role as CEO. Nik is a results-oriented and empathetic leader who highly values our company culture. He is committed to retaining our mantra that sees employee engagement translate into industry-leading study delivery and from that we derive financial health. 

“This is an amazing opportunity to guide Catalyst Clinical Research through its next period of growth and expand on its strengths,” Nik Morton said. “My executive team and I will remain focused on delivering results for our clients and retaining the best employees in the clinical research industry.” 

Prior to Nik joining Catalyst, he held strategic roles at PPD, including global leaderships roles for biostatistics, programming, medical writing, including functional services delivery; hematology and oncology project management overseeing full-service delivery; site and patient access, accountable for selecting the best sites for enrolling and for activating in the shortest cycle times; and the design and implementation of digitally enabled and decentralized clinical trials. 

Other changes in the Catalyst leadership team include 

  • Craig McIlloney has moved into the senior vice president role overseeing Catalyst Flex 
  • Keya Watkins has moved into the senior vice president role overseeing all of Catalyst Oncology 

 
With these changes, Catalyst will strengthen its focus on inspiring our clients to design and deliver better clinical trials.